HealthCap is a European venture capital firm investing exclusively and globally in life sciences. The investment strategy focuses on diseases with high unmet medical needs and breakthrough therapies that have the potential to be transformative and change medical practice, and the lives of patients suffering these conditions.
Having raised more than EUR 1.2 billion since 1996, HealthCap has backed and built more than 125 companies, taken more than 45 companies public and done numerous trade sales.
Over the years, HealthCap companies have developed more than 25 pharmaceutical products to market approval, many of which are breakthrough therapies helping patients with life-threatening diseases. In addition, HealthCap companies have brought more than 50 innovative medical device products to market. These products have generated significant value to many stakeholders, including patients, physicians and society, and as a result also to HealthCap investors.
Since the start in 1996, HealthCap funds have invested in 126 portfolio companies.
46 of the portfolio companies have been taken public on fourteen different markets.
30 of the portfolio companies’ pharmaceutical products have been approved for marketing.
Unicorn Factory Since the start in 1996, HealthCap has helped build 12 companies with a valuation of USD 1 billion or more and 34 companies with a valuation of SEK 1 billion or more.